SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RAY WACLAWSKY who wrote (757)6/19/1997 12:09:00 AM
From: John Metcalf   of 2742
 
Fair question, Ray, "Why is it in (management's) best interest to see the stock go higher?"

In a word: ownership.

Dr. Grausz (who has resigned) owned nearly 6,000,000 shares according to the 10-K (it's on EDGAR, and every CIST owner should read it).

CEO, Bruce Galton owned 1,302,126 options in-the-money, and 109,341 out-of-the-money (at $.375). He has plenty of time, because his options will not expire until April, 2006 and November, 2005. He has a five year employment contract that runs through April, 1999.

Isidore Edelman owned 2,411,681 shares.

In a nutshell, a penny rise in the bid is worth $13,000 to Galton, and puts him one penny closer to more options at $.375. A penny rise is worth $24k to Edelman, and $60k to Grausz.

Also, each non-employee director gets 50,000 options for each year of service, up to 150,000 maximum. So they're probably focused more on a dime or a dollar rise in the bid, which would be worth $15,000 or $150k.

Edelman, Galton, and Grausz are certainly more motivated than any of us to see a high stock price. No one in this thread has yet appeared on the 5% owner registration list -:)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext